Table 1 Clinical characteristics of 874 lung cancer patients treated with paclitaxel-based chemotherapy
Description of patients who received taxane-based chemotherapy | |
|---|---|
Total (N = 874) | |
Age at Diagnosis | |
Mean (SD) | 61.8 (10.4) |
Median (range) | 63.0 (34.0-86.0) |
Gender | |
Female | 392 (44.9%) |
Male | 482 (55.1%) |
Cigarette smoking status | |
Never smokers | 158 (18.1%) |
Former smokers | 428 (49%) |
Current smokers | 273 (31.2%) |
Some smokers | 15 (1.7%) |
Stage | |
SCLC | |
Limited | 37 (4.2%) |
Extensive | 39 (4.5%) |
NSCLC | |
Stage I and II | 153 (17.5%) |
Stage III | 328 (37.5%) |
Stage IV | 317 (36.3%) |
Histologic cell type | |
Adenocarcinoma/bronchioloalveolar carcinoma | 465 (53.2%) |
Squamous cell carcinoma | 162 (18.5%) |
Small cell carcinoma | 76 (8.5%) |
Large cell carcinoma | 28 (3.2%) |
Mixed and unspecified NSCLC | 131 (15.0%) |
Others | 12 (1.4%) |
Tumor differentiation grade | |
Well differentiated | 76 (8.7%) |
Moderately differentiated | 332 (38.0%) |
Poor/undifferentiated | 395 (45.2%) |
Nongradable or unknown | 71 (8.1%) |
Surgery, chemotherapy, radiation | |
Chemotherapy | 238 (27.2%) |
Surgery & chemotherapy | 157 (18%) |
Radiation & chemotherapy | 311 (35.6%) |
Surgery & radiation & chemotherapy | 168 (19.2%) |